Filing Details
- Accession Number:
- 0001181431-14-039852
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-12-30 19:21:16
- Reporting Period:
- 2014-12-29
- Filing Date:
- 2014-12-30
- Accepted Time:
- 2014-12-30 19:21:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1396814 | Pacira Pharmaceuticals Inc. | PCRX | Pharmaceutical Preparations (2834) | 510619477 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1288231 | Phd P John Longenecker | C/O Pacira Pharmaceuticals, Inc. 5 Sylvan Way, Suite 300 Parsippany NJ 07054 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-12-29 | 1,000 | $29.90 | 1,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2014-12-29 | 1,000 | $93.32 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2014-12-29 | 1,000 | $0.00 | 1,000 | $29.90 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 3,000 | 2023-06-11 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- The option shares vest in 12 equal successive monthly installments over the 12-month period following the date of grant, subject to the reporting person's continued service as a director.
Billionaire Hedge Funds
